{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:40:26Z","timestamp":1779882026600,"version":"3.53.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bneo.2024.100042","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T17:04:22Z","timestamp":1726506262000},"page":"100042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma"],"prefix":"10.1016","volume":"1","author":[{"given":"Eunice","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1995-2170","authenticated-orcid":false,"given":"Yu Yang","family":"Soon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainsley Ryan Yan Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2024-7476","authenticated-orcid":false,"given":"Shi Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinnie Yentia","family":"Soekojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-0655","authenticated-orcid":false,"given":"Melissa","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8881-3537","authenticated-orcid":false,"given":"Sanjay","family":"de Mel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10272","key":"10.1016\/j.bneo.2024.100042_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bneo.2024.100042_bib2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.bneo.2024.100042_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.bneo.2024.100042_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjh.17410","article-title":"Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology\/UK Myeloma Forum guideline","volume":"193","author":"Sive","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.bneo.2024.100042_bib5","first-page":"2261","article-title":"Future directions in maintenance therapy in multiple myeloma","volume":"10","author":"Holstein","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"19","key":"10.1016\/j.bneo.2024.100042_bib6","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.bneo.2024.100042_bib7","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3324\/haematol.2020.247130","article-title":"Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial","volume":"106","author":"Jackson","year":"2020","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.bneo.2024.100042_bib8","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.bneo.2024.100042_bib9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.bneo.2024.100042_bib10","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.bneo.2024.100042_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.bneo.2024.100042_bib12","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.bneo.2024.100042_bib13","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"10168","key":"10.1016\/j.bneo.2024.100042_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"issue":"34","key":"10.1016\/j.bneo.2024.100042_bib15","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1200\/JCO.20.02060","article-title":"Ixazomib vs placebo as post-induction maintenance therapy in newly diagnosed multiple myeloma (NDMM) patients (PTS) not undergoing autologous stem cell transplant (ASCT): phase 3 tourmaline-mm4 trial","volume":"38","author":"Dimopoulos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2024.100042_bib16","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2024.100042_bib17","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2024.100042_bib18","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","article-title":"Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis","volume":"4","author":"Gay","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.bneo.2024.100042_bib19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"7650","key":"10.1016\/j.bneo.2024.100042_bib20","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.bneo.2024.100042_bib21","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3324\/haematol.2019.240374","volume":"105","author":"Zweegman","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bneo.2024.100042_bib22","article-title":"Long-term efficacy of maintenance therapy for multiple myeloma: a quantitative synthesis of 22 randomized controlled trials","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100042_bib23","first-page":"1832","article-title":"A systematic review and network meta-analysis of maintenance treatment for patients with newly diagnosed multiple myeloma post-autologous stem cell transplant","volume":"130","author":"Schmitz","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2024.100042_bib24","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/16078454.2021.2009648","article-title":"Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis","volume":"26","author":"Chen","year":"2021","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.bneo.2024.100042_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/ejh.13506","article-title":"Efficacy of proteasome inhibitor-based maintenance following autologous transplantation in multiple myeloma: a systematic review and meta-analysis","volume":"106","author":"Parrondo","year":"2021","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100042_bib26","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/blood-2019-130644","volume":"134","author":"Vij","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2024.100042_bib27","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-21-3420","article-title":"Safety and efficacy of combination maintenance therapy with ixazomib and lenalidomide in patients with posttransplant myeloma","volume":"28","author":"Patel","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.bneo.2024.100042_bib28","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma","volume":"142","author":"Rosi\u00f1ol","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2024.100042_bib29","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2024.100042_bib30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","article-title":"Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Dytfeld","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2024.100042_bib31","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2024.100042_bib32","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, & dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2024.100042_bib33","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100042_bib34","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2019-123401","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma: overall survival in alcyone","volume":"134","author":"Mateos","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2024.100042_bib35","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bneo.2024.100042_bib36","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100042_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2024.100042_bib38","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"29","key":"10.1016\/j.bneo.2024.100042_bib39","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.bneo.2024.100042_bib40","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.2022018339","article-title":"Optimizing the value of lenalidomide maintenance by genetic profiling - an analysis of 556 Myeloma XI trial patients","volume":"141","author":"Panopoulou","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2024.100042_bib41","article-title":"Daratumumab-based induction therapy for multiple myeloma: a systematic review and meta-analysis","volume":"159","author":"Chong","year":"2020","journal-title":"Crit Rev Oncol-Hematol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T07:06:57Z","timestamp":1735715217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2950328024000426"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100042","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100042"}}